The Company is an early stage biopharmaceutical company dedicated to the commercial translation of the clinical knowledge and insights of Dr. Alan Shackelford, gained through his treatment of more than 25,000 patients using endocannabinoid therapies.
Dr. Shackelford is a Harvard Medical School trained internist and researcher who is one of the world’s foremost authorities on the clinical uses of cannabinoids and is recognized for pioneering the treatment of Dravet Syndrome with cannabinoids. Over the last decade, he treated patients suffering from a variety of medical ailments, targeting the endocannabinoid system using his unique formulations. Dr. Shackelford has worked with a number of American state and Canadian provincial government agencies on establishing governance of medical cannabis programs and has advised foreign governments on their cannabis regulations.
At Shackelford Pharma, Dr. Shackelford is supported by an expert medical and pharmaceutical team with a wealth of experience in clinical research and development, drug development, commercial operations, and marketing, to manage the development and commercialization of pharmaceutical products.
The Company aims to provide physicians with the knowledge and confidence to prescribe cannabinoid-based therapies and provide patients with the certainty that the products are safe, consistent, and most importantly, effective.
SPI is dedicated to alleviating human suffering through the development of pharmaceutical grade endocannabinoid-based therapies for a range of health disorders. Our goal is to become the global leader in the development and commercialization of endocannabinoid-based medical products that address unmet medical needs, meet the quality standards of the pharmaceutical industry, comply with the legal and regulatory environments in major markets, provide clinicians with the confidence to treat their patients, and offer patients and consumers assurance of quality and consistency beyond that provided by products based on recreational cannabis.
